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Abstract The diagnostic reliability and prognostic implica-
tions of procalcitonin (PCT) (ng/ml) on admission in patients
with community-acquired pneumonia (CAP) due to Legionella
pneumophila are unknown. We retrospectively analysed
PCT values in 29 patients with microbiologically proven
Legionella-CAP admitted to the University Hospital Basel,
Switzerland, between 2002 and 2007 and compared them to
other markers of infection, namely, C-reactive protein (CRP)
(mg/l) and leukocyte count (109/l), and two prognostic
severity assessment scores (PSI and CURB65). Laboratory
analysis demonstrated that PCT values on admission were
>0.1 in over 93%, >0.25 in over 86%, and >0.5 in over 82% of
patients with Legionella-CAP. Patients with adverse medical
outcomes (59%, n=17) including need for ICU admission
(55%, n=16) and/or inhospital mortality (14%, n=4) had
significantly higher median PCT values on admission (4.27
[IQR 2.46–9.48] vs 0.97 [IQR 0.29–2.44], p=0.01), while the
PSI (124 [IQR 81–147] vs 94 [IQR 75–116], p=0.19), the
CURB65 (2 [IQR 1–2] vs 1 [1–3], p=0.47), CRP values (282
[IQR 218–343], p=0.28 vs 201 [IQR 147–279], p=0.28), and
leukocyte counts (12 [IQR 10–21] vs 12 [IQR 9–15], p=0.58)
were similar. In receiver operating curves, PCT concentrations
on admission had a higher prognostic accuracy to predict
adverse outcomes (AUC 0.78 [95%CI 0.61–96]) as compared
to the PSI (0.64 [95%CI 0.43–0.86], p=0.23), the CURB65
(0.58 [95%CI 0.36–0.79], p=0.21), CRP (0.61 [95%CI 0.39–
0.84], p=0.19), and leukocyte count (0.57 [95%CI 0.35–
0.78], p=0.12). Kaplan-Meier curves demonstrated that
patients with initial PCT values above the optimal cut-off
of 1.5 had a significantly higher risk of death and/or ICU
admission (log rank p=0.003) during the hospital stay. In
patients with CAP due to Legionella, PCT levels on admission
might be an interesting predictor for adverse medical out-
comes.
Introduction
In patients with clinical suspicion of community-acquired
pneumonia (CAP), procalcitonin (PCT) (ng/ml) has a high
diagnostic accuracy to differentiate bacterial from nonbacte-
rial causes [1, 2]. Several intervention studies have demon-
strated that PCT-guided antibiotic therapy can markedly
reduce antibiotic exposure in patients presenting with CAP
without compromising medical outcomes [3–6]. In addition,
repeated PCT measurements have prognostic implications in
critically ill patients in the ICU setting as high or increasing
PCT values correlate with adverse medical outcome [7, 8].
In CAP caused by “atypical” bacteria, including Chlamydia
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pneumoniae and Mycoplasma pneumoniae, lower PCT
values as compared to pneumonia caused by extracellular
bacteria have been reported, questioning the diagnostic
reliability of PCT in atypical CAP [9, 10]. In atypical CAP
caused by Legionella, studies using insensitive PCT assays
have produced controversial results regarding the benefits
and diagnostic reliability of initial PCT measurement [9, 11,
12]. Because Legionella-CAP has a substantial mortality and
complication rate, early diagnosis and monitoring of the
disease course are crucial [13]. The aim of this study was to
assess the prognostic implications of initial PCT measurements
in patients with microbiologically confirmed Legionella-CAP
using a high sensitive PCT assay.
Materials and methods
Setting and study population
This study was conducted at the University Hospital Basel,
Switzerland, a 700-bed primary and tertiary health care centre.
It is the major provider of acute medical care for about
300,000 inhabitants. In this five-year retrospective study we
included all consecutive patients admitted to our institution
between September 2002 and September 2007, in whom
Legionella-CAP was microbiologically diagnosed and a
serum PCT concentration was determined on admission. In
22 patients (76%) PCT levels were also available during the
course of the disease (Fig. 1) and results of PCT testing were
available to the clinicians. Patient records were reviewed with
a standardized data-collection form to retrieve demographic,
clinical, microbiological, radiological, and laboratory data. We
compared the prognostic accuracy of different laboratory and
clinical data with two clinical severity prediction scores,
namely, the pneumonia severity index (PSI) and the CURB65
score [14–16]. This study was approved by the local ethical
committee (EKBB) and as a retrospective quality-surveillance
study, the need for patient informed consent was waived.
Definitions
For this analysis, CAP was defined by the presence of one or
several of the following recently acquired respiratory signs or
symptoms: cough, sputum production, dyspnoea, core body
temperature >38.0°C, auscultatory findings of abnormal breath
sounds and rales, leukocyte count >10 or <4×109 cells/l, and
an infiltrate on chest radiograph [17]. Diagnosis of Legionella
infection was established either by positive Legionella urinary
antigen testing, positive Legionella culture, or PCR of
respiratory specimen (sputum, tracheobronchial aspirate and/
or bronchoalveolar lavage). Adverse medical outcome for this
study was defined as inhospital death and/or need for ICU
admission, respectively, up to the time of hospital discharge.
Data collection
We used available laboratory results including markers of
infection (PCT, C-reactive protein [CRP] (mg/l), leukocyte
count [Lc] (109/l)), liver enzymes (ALAT, ASAT), sodium
concentrations, lactate-dehydrogenase (LDH), and creati-
nine-kinase (CK) from the routinely collected blood
analysis. CRP concentrations were determined by an
enzyme immunoassay having a detection limit of <5 mg/
dl (EMIT, Merck Diagnostica, Zurich, Switzerland). PCT
was measured using 20–50 μl of plasma or serum by a
time-resolved amplified cryptate emission (TRACE) tech-
nology assay (Kryptor PCT, Brahms AG, Hennigsdorf,
Germany) as described elsewhere [3]. The assay has a
functional assay sensitivity of 0.06 μg/l, which is about four-
fold above mean normal levels. Legionella was diagnosed
either by antigen in urine detection using an immunoenzy-
metric commercial method (Legionella Urinary Antigen;
Binax), by PCR using an in-house PCT technique from the
IMM (Institute for Medical Microbiology) in Zurich,
Switzerland, or by culture [18, 19].
Statistical analysis
Discrete variables were expressed as counts (percentage)
and continuous variables as medians and interquartile
ranges (IQR) unless stated otherwise. Frequency compari-
Fig. 1 Course of PCT in patients without an adverse event (a) and in
patients with death and/or ICU admission (b)
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son was done by chi-square test. Two-group comparison of
normally distributed data was performed by Students t test.
For data not normally distributed, the Mann-Whitney U test
was used. Receiver-operating characteristics were calculat-
ed using STATA 9.2 (Stata Corp, College Station, TX).
Levels that were nondetectable were assigned a value equal
to the lower limit of detection for the assay. All testing was
two-tailed and p values less than 0.05 were considered to
indicate statistical significance.
Results
Baseline parameters
From a total of 82 patients with Legionella-CAP admitted
between September 2002 and September 2007 to our
institution, 29 patients (35%) had a measurement of PCT
on admission and were thus included in this analysis. The
53 patients with Legionella-CAP and without initial PCT
measurement were similar in terms of age (p=0.68), gender
(0.78), severity of disease as assessed by the PSI score (p=
0.13), initial CRP concentration (p=0.95), initial leukocyte
count (p=0.78), and occurrence of adverse medical out-
comes (p=0.11).
Table 1 presents baseline characteristics including demo-
graphic, clinical, and laboratory data of the patients with
Legionella-CAP. Patients were predominantly male (66%)
with a median age of 68 years (IQR 53–77 years). Clinical
examination showed a median body temperature of 39.6°C
(IQR 38.8–40.3), median systolic blood pressure of
122 mmHg (IQR 113–139) and median heart rate of
105 bps (IQR 91–120). Hyponatremia (sodium concentration
<131 mmol/l) was present in 41% (n=12), thrombocytopenia
(thrombocytes <150×109/l) in 24% (n=7), increased lactate
dehydrogenase (LDH) (>225 U/l) and creatinine kinase (CK)
(>220 U/l) in 66% (n=19) and 48% (n=14) of patients,
respectively. Laboratory analysis demonstrated median PCT
(ng/ml), C-reactive protein (CRP) (mg/l), and leukocyte count
(Lc) (109/l) concentrations on admission of 2.9 (IQR 0.93–
6.43), 240 (IQR 173–310), and 12.1 (IQR 9.4–15.9),
respectively. Initial PCT values were >0.1 in over 93%,
>0.25 in over 86%, and >0.5 in over 82% of patients.
The diagnostic work-up of Legionella infection in the 29
patients included positive urine antigen testing in 82% (23/
28), positive respiratory sample culture in 32% (6/19),
positive PCR in 100% (11/11), and positive serology in
50% (1/2). Because in most patients multiple diagnostic
tests for Legionella-CAP were performed to establish the
diagnosis, percentages may not sum up to 100%.
Calculation of prognostic scores demonstrated a median
PSI score of 109 (range 81–140) and a median CURB65
score of 1 (IQR 1–2). The median length of hospital stay
was 12 days (IQR 8–20). Adverse medical outcomes were
noted in 59% of the patients (n=17) including 55%
admissions to the ICU (n=16) and/or death in 14% (n=4).
Figure 1 illustrates PCT values on admission and during
the hospital stay in patients with and in patients without
adverse outcomes. PCT values on admission were signif-
icantly higher in patients with ICU admission and/or death
(4.27 [IQR 2.46–9.48] vs 0.97 [IQR 0.29–2.44], p=0.01).
Table 1 Baseline characteristics in patients with community-acquired
pneumonia due to Legionella (n=29)
Baseline characteristics Value
Demographic characteristics
- Age (y) 68 (53–77)a
- Gender (male), n (%) 19 (66)
Coexisting illnesses, n (%)
- Congestive heart disease 5 (17)
- Cerebrovascular disease 3 (10)
- Renal dysfunction 3 (10)
- COPD 3 (10)
- Neoplastic disease 2 (7)
- Liver disease 5 (17)
Clinical and laboratory findings
- Confusion, n (%) 5 (18)
- Respiratory rate (breaths/min) 18 (16–29)a
- Systolic blood pressure (mmHg) 122 (113–139)a
- Heart rate (beats/min) 105 (91–120)a
- Body temperature (°C) 39.6 (38.8–40.3)a
- Pleural effusion, n (%) 11 (38)
Laboratory findings
- C-reactive protein (mg/l) 240 (173–310)a
- Procalcitonin (μg/l) 2.90 (0.93–6.43)a
- Hematocrit (%) 37 (35–41)a
- Leukocyte count (×109/l) 12.1 (9.4–15.9)a
- Platelets count (×109/l) 200 (153–257)a
- Sodium (mmol/l) 132 (129–134)a
- Creatinine (umol/l) 100 (69–130)a
- Urea (mmol/l) 7.6 (5.2–12.8)a
- Elevated liver enzymesb, n (%) 21 (72)
- CK (U/l) 175 (48–742)a
- LDH (U/l) 253 (186–354)a
- Glucose (mmol/l) 7.1 (6.2–10.7)a
- Oxygen saturation (%) 95 (90–96)a
- PaO2 (kPa) 7.6 (7.2–10.6)
a
- pH 7.45 (7.42–7.49)a
Risk assessment
- PSI points 109 (81–140)a
- CURB65 1 (1–2)a
Outcome
- Death, n (%) 4 (14)
- Admission to ICU, n (%) 16 (55)
COPD chronic obstructive pulmonary disease, CK creatinine-kinase,
LDH lactate-dehydrogenase, PSI pneumonia severity index
CURB65 Confusion, Urea, Respiratory Rate, Blood Pressure, Age >65
a Denotes median (interquartile range)
b Denotes ASAT and/or ALAT
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Patients with adverse medical outcomes had similar PSI
scores (124 [IQR 81–147] vs 94 [IQR 75–116], p=0.19),
similar CURB65 scores (2 [IQR 1–2] vs 1 [IQR1–3], p=
0.47), similar CRP values (282 [IQR 218–343] vs 201 [IQR
147–279], p=0.28), and similar leukocyte count (12 [IQR
10–21] vs 12 [IQR 9–15], p=0.58) as compared to those
without adverse outcome (Fig. 2). In addition, initial
clinical parameters including total body temperature,
diastolic and systolic blood pressure and pulse frequency,
and other laboratory analysis including thrombocyte levels,
sodium concentrations, liver enzyme concentrations, LDH
and CK levels in patients with and without adverse
outcomes were similar.
To assess the prognostic usefulness of the different
parameters, we calculated receiver operating curves (ROC)
with the area under the curve (AUC) as an overall
prognostic measure of the parameter. PCT concentrations
on admission had the highest prognostic accuracy to predict
adverse medical outcome (AUC 0.78 [95%CI 0.61–0.96]), as
compared to CRP (0.61 [95%CI 0.39–0.84], p=0.19) and
leukocyte count (0.57 [95%CI 0.35–0.78], p=0.12), and
compared to the PSI (0.64 [95%CI 0.43–0.86], p=0.23)
and the CURB65 score (0.58 [95%CI 0.36–0.79], p=0.21).
At an optimal PCT cut-off of 1.5 the sensitivity and
specificity to predict adverse outcome was 82% (95%CI
57–96%) and 75% (95%CI 43–94%) with corresponding
positive and negative likelihood ratios of 3.3 and 0.24.
Likewise, at a PCT cut-off of 0.5, sensitivities and
specificities to predict adverse outcome were 94% (95%CI
71–99%) and 33% (95%CI 10–65%), respectively, with
corresponding positive and negative likelihood ratios of 1.41
and 0.18, respectively.
To illustrate the capacity of initial PCT for risk
assessment in patients with Legionella-CAP admitted to
the emergency departement, we performed a comparison of
adverse medical outcome in patients with PCT below and
above the optimal cut-off of 1.5 by Kaplan-Meier curves
(Fig. 3). Patients with PCT levels above this cut-off had a
significantly higher risk for adverse medical outcome
during the hospital stay as compared to patients below the
cut-off (log-rank test p=0.003).
Fig. 2 Prognostic assessment in
patients with community-
acquired pneumonia due to
Legionella
Fig. 3 Kaplan Meier curves depicting time to adverse medical
outcome stratified by initial PCT value (optimal PCT cut-off value
of 1.5 ng/ml)
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Discussion
In this study we found increased PCT values in the large
majority of patients, namely, PCT concentrations >0.1 in
over 93% and >0.25 in over 86% of patients using a high
sensitive PCT assay. Importantly, the initial PCT concen-
trations had a high prognostic accuracy to predict adverse
medical outcomes including inhospital mortality and/or
need for ICU admission.
In bacterial infection, microbial antigens stimulate
different pro- and antiinflammatory mediators, which
eventually penetrate into the blood circulation where they
can be measured. In recent years, PCT has emerged as a
surrogate biomarker for bacterial infections, because PCT
concentrations correlate with the likelihood and the severity
of bacterial infections [1, 2]. Based on these considerations,
a new strategy to reduce antibiotic exposure in patients with
lower respiratory tract infections is guidance of antibiotic
therapy based on PCT cut-off ranges [3–6]. Because
different microbes might induce a distinct response in
different organs resulting in a variable increase of PCT
blood concentrations, reassurance of the diagnostic reliabil-
ity of PCT to detect relevant infections caused by distinct
pathogens is of relevance. This study confirms that unlike
in mild atypical CAP caused by Chlamydia pneumoniae
and Mycoplasma pneumoniae, PCT levels increase to a
higher extent in severe atypical CAP caused by Legionella
species [9, 10]. Importantly, the increase of PCT had a
higher prognostic accuracy as compared to the PSI to
predict unfavourable outcomes, thus confirming prior
studies in Legionella-CAP and in critically ill patients in
the ICU setting [7, 11]. The finding of initially high PCT
values in patients with adverse outcome is of particular
importance with regard to PCT-guided antibiotic therapy in
CAP and the possibility of initially withholding antibiotic
therapy and reassessing PCT values after 6–24 hours in
patients with low PCT values [20, 21].
A previous study has focussed on PCT in Legionella-
CAP patients using a semiquantitative PCT assay. They
reported high frequencies of “negative” PCT results when a
cut-off value of 0.5 was applied [11]. High sensitive PCT
measurements, as used in this study, provide an increase in
diagnostic reliability, especially in sensitivity, and thus in
the safety of patients. Our findings underline the impor-
tance of the use of more sensitive PCT assays to appreciate
its full diagnostic potential [22]. In addition, using PCT cut-
off ranges instead of a single cut-off value reflects more
physiologically the interindividual variability of the in-
crease of PCT upon bacterial infections.
With a retrospective design, this study has limitations
and the results need prospective confirmation. The fact that
physicians were not blinded and thus aware of PCT results
may have influenced their decision to transfer patients to
the ICU. In addition, in a prospective study, without the
results of Legionella testing in real-time, the prognostic
information of PCT may be difficult. Observational studies
have produced contradictory results regarding the diagnos-
tic reliability of PCT in CAP, mainly because the causative
microorganisms in presumed bacterial CAP cannot be
detected in most patients [2, 23, 24]. This study circum-
vents this “gold standard dilemma” because it only includes
patients with microbiologically proven Legionella-CAP.
Because testing for Legionella using urine antigen testing
is mandatory in our institution, in the initial work-up of all
patients with CAP, it is reasonable to believe that we
included the majority of Legionella-CAP patients. Another
important limitation of this study is the small sample size
restricting the statistical power, particularly of the ROC
statistics. Thus, despite numerical differences in the AUCs,
statistical differences were not detected. The high number
of adverse medical outcomes found in this study may be
particular for a referred Legionella-CAP population from a
University Hospital, thus limiting the generalisability of this
study.
In conclusion, increased PCT concentrations were found
in the large majority of patients with Legionella-CAP,
predicting worse outcome. If confirmed in future studies,
PCT could be an interesting prognostic tool complementing
clinical severity prediction scores.
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